CoChat

Real-world depression, anxiety and safety outcomes of intramuscular ketamine treatment: a retrospective descriptive cohort study

Open access
Ahuja, Sachin, Brendle, Madeline, Smart, Leo, Moore, Claire, Thielking, Paul, Robison, Reid · 2022 · BMC Psychiatry

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Abstract

Background: Ketamine has emerged as a promising pharmacotherapy for depression and other mental illnesses, and the intramuscular (IM) administration of ketamine is now offered at many North American outpatient psychiatric clinics. However, a characterization of the outpatient population receiving IM ketamine treatment and an evaluation of the real-world depression, anxiety, and safety outcomes of long-term psychiatric IM ketamine treatment has not been reported. This study aimed to evaluate the clinical characteristics, treatment patterns, clinical outcomes, and adverse events of patients receiving IM ketamine treatment. Methods: Patient data from the electronic health records of a private outpatient psychiatric clinic network in the United States were collected and analyzed retrospectively. Adults with any psychiatric diagnosis who received ketamine treatment only by IM administration from January 2018 to June 2021 were included. A total of 452 patients were included in the cohort. Results: Patients receiving IM ketamine treatment had a mean of 2.8 (SD 1.4) psychiatric diagnoses. 420 (93%) patients had a diagnosis of major depressive disorder, 243 (54%) patients had a diagnosis of generalized anxiety disorder, and 126 (28%) patients had a diagnosis of post-traumatic stress disorder. Patients received a median of 4 (range 1–48) IM ketamine treatments. Median depression scores (PHQ-9) improved 38% from 16.0 (IQR 11.3–21.8) at baseline to 10.0 (IQR 6.0–15.0) at last treatment (p < .001). Median anxiety scores (GAD-7) improved 50% from 14.0 (IQR 8.0–17.0) at baseline to 7.0 (IQR 4.3–11.8) at last treatment (p < .001). With maintenance ketamine treatments, average improvements in depression (PHQ-9) and anxiety (GAD-7) scores of at least 4.7 and 4.9 points were maintained for over 7 months. An adverse event occurred during 59 of 2532 treatments (2.3%). Conclusions: IM ketamine is being utilized to treat psychiatric outpatients with multiple mental illnesses not limited to depression. Average depression and anxiety levels significantly improve throughout IM ketamine treatment and do not regress to baseline during patients’ maintenance treatment phase. Prospective studies are recommended to confirm the long-term effectiveness and safety of IM ketamine.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12888-022-04268-5

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Time between successive IM ketamine treatment sessions 1–12
Fig. 1 Time between successive IM ketamine treatment sessions 1–12CC BY · PubMed Central
Fig. 2 IM Ketamine doses (mg/kg) throughout treatment sessions 1–6
Fig. 2 IM Ketamine doses (mg/kg) throughout treatment sessions 1–6CC BY · PubMed Central
Fig. 3 Change in depression and anxiety scores throughout IM ketamine treatments 1–12
Fig. 3 Change in depression and anxiety scores throughout IM ketamine treatments 1–12CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Research works printed but not linked: 1

  1. Johnson & Johnson. Janssen Announces U.S. FDA approval of SPRAVATO® (esketamine) CIII nasal spray to treat depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior: Johnson & Johnson; 2020. https://www.jnj.com/janssen-announces-u-s-fda-approval-of-spravato-esketamine-ciii-nasal-spray-to-treat-depressive-symptoms-in-adults-with-major-depressive-disorder-with-acute-suicidal-ideation-or-behavior. Accessed 5 Jun 2022

Cited by

See all 32

Metadata

Authors
Ahuja, S., Brendle, M., Smart, L., Moore, C., Thielking, P., & Robison, R.
Affiliations
University of Utah (US)
Corresponding author
  • Ahuja, Sachin
  • Robison, Reid
Venue
BMC Psychiatry
Published
2022-10-03
Volume
22
Issue
1
Pages
634-634
ISSN
1471-244X (ISSN-L)
OpenAlex
W4300963487
Cited by
24
References
41
Citations by year
2026: 8 · 2025: 6 · 2024: 4 · 2023: 6
FWCI
2.39
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Psychiatry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
Keywords
intramuscular ketamine, major depressive disorder, generalized anxiety disorder, post-traumatic stress disorder, treatment-resistant depression, adverse events, psychiatric outpatients, PHQ-9, GAD-7, long-term treatment outcomes, psychiatric comorbidity, outpatient psychiatric care, treatment patterns, treatment discontinuation
MeSH terms
Adult, Anxiety, Anxiety Disorders, Depression, Depressive Disorder, Major, Major Depressive Disorder, Humans, Ketamine, Prospective Studies, Psychiatric Status Rating Scales, Retrospective Studies, Cohort Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Real-world depression, anxiety and safety outcomes of intramuscular ketamine treatment: a retrospective descriptive cohort study. https://app.cochat.ai/papers/10.1186/s12888-022-04268-5
The paper
Ahuja, S., Brendle, M., Smart, L., Moore, C., Thielking, P., & Robison, R. (2022). Real-world depression, anxiety and safety outcomes of intramuscular ketamine treatment: a retrospective descriptive cohort study. BMC Psychiatry. https://doi.org/10.1186/s12888-022-04268-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.